Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD19 + status confers therapeutic sensitivity to Blinatumomab in patients with Acute Lymphoid Leukemia.
This statement is based on a regulatory approval from the Health Canada:
BLINCYTO (blinatumomab for injection) is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor ALL.